Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1

  • White, Michelle (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date15/08/22 → 14/08/27

Keywords

  • randomised controlled trial
  • treatment efficacy
  • treatment safety
  • breast cancer